| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 131,705 | 59,997 |
| Depreciation and amortization | 16,196 | 10,645 |
| Amortization of premiums, discounts and issuance costs | 698 | 458 |
| Impairment losses | 0 | 0 |
| Loss on disposal of businesses | 0 | 0 |
| Net gain on investments in divested businesses | 20,906 | - |
| Stock-based compensation expense | 12,700 | 7,550 |
| Deferred income taxes | 27,639 | 16,504 |
| Other | 3,386 | 1,501 |
| Accounts receivable | -29,101 | -21,231 |
| Prepaid expenses and other current assets | 784 | -204 |
| Other long-term assets | -16,972 | -9,601 |
| Accounts payable and accrued expenses | -38,833 | -89,951 |
| Payment of contingent consideration liability | 318 | - |
| Income taxes payable | 9,377 | 4,763 |
| Long-term professional liabilities | -7,406 | -8,166 |
| Other liabilities | -12,620 | -9,315 |
| Net cash provided by operating activities - continuing operations | 160,135 | 22,020 |
| Net cash used in operating activities - discontinued operations | -3,146 | -2,316 |
| Net cash provided by operating activities | 156,989 | 19,704 |
| Acquisition payments, net of cash acquired | 19,196 | 0 |
| Purchases of investments | 23,484 | 21,529 |
| Proceeds from maturities or sales of investments | 21,424 | 18,380 |
| Proceeds from investment in divested business | 30,000 | - |
| Purchases of property and equipment | 13,171 | 7,833 |
| Other | 3,587 | 3,636 |
| Net cash used in investing activities | -8,014 | -14,618 |
| Borrowings on line of credit | 0 | 0 |
| Payments on line of credit | 0 | 0 |
| Payments on term loan | 14,063 | 9,375 |
| Payment on finance lease obligation | 1,346 | 844 |
| Payment of contingent consideration liability | 3,182 | - |
| Proceeds from issuance of common stock | 2,538 | 1,838 |
| Repurchases of common stock | 22,645 | 1,778 |
| Other | -158 | -135 |
| Net cash provided by financing activities | -38,856 | -10,294 |
| Net increase in cash and cash equivalents | 110,119 | -5,208 |
| Cash and cash equivalents at beginning of period | 229,940 | - |
| Cash and cash equivalents at end of period | 340,059 | - |
Pediatrix Medical Group, Inc. (MD)
Pediatrix Medical Group, Inc. (MD)